Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/18631
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRenfro, Lindsay A-
dc.contributor.authorLoupakis, Fotios-
dc.contributor.authorAdams, Richard A-
dc.contributor.authorSeymour, Matthew T-
dc.contributor.authorHeinemann, Volker-
dc.contributor.authorSchmoll, Hans-Joachim-
dc.contributor.authorDouillard, Jean-Yves-
dc.contributor.authorHurwitz, Herbert-
dc.contributor.authorFuchs, Charles S-
dc.contributor.authorDiaz-Rubio, Eduardo-
dc.contributor.authorPorschen, Rainer-
dc.contributor.authorTournigand, Christophe-
dc.contributor.authorChibaudel, Benoist-
dc.contributor.authorFalcone, Alfredo-
dc.contributor.authorTebbutt, Niall C-
dc.contributor.authorPunt, Cornelis J A-
dc.contributor.authorHecht, J Randolph-
dc.contributor.authorBokemeyer, Carsten-
dc.contributor.authorVan Cutsem, Eric-
dc.contributor.authorGoldberg, Richard M-
dc.contributor.authorSaltz, Leonard B-
dc.contributor.authorde Gramont, Aimery-
dc.contributor.authorSargent, Daniel J-
dc.contributor.authorLenz, Heinz-Josef-
dc.date2015-10-26-
dc.date.accessioned2018-08-30T06:34:04Z-
dc.date.available2018-08-30T06:34:04Z-
dc.date.issued2016-01-10-
dc.identifier.citationJournal of Clinical Oncology 2016-01-10; 34(2): 144-50-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/18631-
dc.description.abstractIn recent retrospective analyses of early-stage colorectal cancer (CRC), low and high body mass index (BMI) scores were associated with worsened outcomes. Whether BMI is a prognostic or predictive factor in metastatic CRC (mCRC) is unclear. Individual data from 21,149 patients enrolled onto 25 first-line mCRC trials during 1997 to 2012 were pooled. We assessed both prognostic and predictive effects of BMI on overall survival and progression-free survival, and we accounted for patient and tumor characteristics and therapy type (targeted v nontargeted). BMI was prognostic for overall survival (P < .001) and progression-free survival (P < .001), with an L-shaped pattern. That is, risk of progression and/or death was greatest for low BMI; risk decreased as BMI increased to approximately 28 kg/m(2), and then it plateaued. Relative to obese patients, patients with a BMI of 18.5 kg/m(2) had a 27% increased risk of having a PFS event (95% CI, 20% to 34%) and a 50% increased risk of death (95% CI, 43% to 56%). Low BMI was associated with poorer survival for men than women (interaction P < .001). BMI was not predictive of treatment effect. Low BMI is associated with an increased risk of progression and death among the patients enrolled on the mCRC trials, with no increased risk for elevated BMI, in contrast to the adjuvant setting. Possible explanations include negative effects related to cancer cachexia in patients with low BMI, increased drug delivery or selection bias in patients with high BMI, and potential for an interaction between BMI and molecular signaling pathways.-
dc.language.isoeng-
dc.titleBody Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database.-
dc.typeJournal Article-
dc.identifier.journaltitleJournal of Clinical Oncology-
dc.identifier.affiliationMemorial Sloan-Kettering Cancer Center, New York, NYen
dc.identifier.affiliationUniversity Hospital Leuven, Leuven, Belgiumen
dc.identifier.affiliationOhio State University, Columbus, OHen
dc.identifier.affiliationMayo Clinic, Rochester, MNen
dc.identifier.affiliationAzienda Ospedaliero-Universitaria Pisana and Università di Pisa, Pisa, Italyen
dc.identifier.affiliationCardiff University, Cardiffen
dc.identifier.affiliationSt James's Hospital and University of Leeds, Leeds, United Kingdomen
dc.identifier.affiliationUniversity of Munich, Munichen
dc.identifier.affiliationUniversity Clinic Halle (Saale), Halleen
dc.identifier.affiliationKlinikum Bremen-Ost Klinik für Innere Medizin, Bremenen
dc.identifier.affiliationUniversity Hospital Cancer Center, University Hospital, Hamburg-Eppendorf, Germanyen
dc.identifier.affiliationInstitut de Cancerologie, Centre René Gauducheau, Nantesen
dc.identifier.affiliationUniversity of Paris Est Creteil, Henri-Mondor Hospital, Créteilen
dc.identifier.affiliationFranco-British Institute, Levallois-Perret, Franceen
dc.identifier.affiliationDuke University Medical Center, Durham, NCen
dc.identifier.affiliationDana-Farber Cancer Institute Boston, MAen
dc.identifier.affiliationInstituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spainen
dc.identifier.affiliationAustin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationAcademic Medical Center, University of Amsterdam, Amsterdam, the Netherlandsen
dc.identifier.affiliationDavid Geffen School of Medicine at the University of California at Los Angelesen
dc.identifier.affiliationUniversity of Southern California/Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CAen
dc.identifier.doi10.1200/JCO.2015.61.6441-
dc.identifier.pubmedid26503203-
dc.type.austinJournal Article-
dc.type.austinMeta-Analysis-
dc.type.austinResearch Support, Non-U.S. Gov't-
local.name.researcherTebbutt, Niall C
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.languageiso639-1en-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

10
checked on Mar 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.